Evommune reports Phase 2a data for EVO301 in atopic dermatitis at EADV
The IL-18 inhibitor hit its primary endpoint at Week 12 and the company plans to start a Phase 2b subcutaneous trial in mid-2027.
SEC filing
Every FDA, SEC, and trial development, traced to its source.
readthrough reads the FDA, the SEC, and ClinicalTrials.gov as they update, writes an original summary of each development, and links every sentence to the document it came from. No trade press. No wire copy. Just the record, on the companies you watch. What we cover, and what we don’t yet.
2,208 listed biopharma companies · 14,673 primary documents · 3 regulators, polled around the clock
How it works
1
Watch
Pick the companies, drugs, and targets you follow, or start from a curated list: big pharma, oncology, cardiometabolic, rare disease, and more.
2
Read
Each new filing, approval, recall, or trial change becomes a short original story. Every claim cites the document it came from, and each story is checked against those documents before it publishes.
3
Get it where you work
A morning email digest at the hour you choose, private RSS feeds, Slack or Teams posts, and search across the whole record.
From the feed this week
Agomab reports positive OLE data for ontunisertib in Crohn's bowel strictures
The company said results from the 48-week extension study support starting a global Phase 2b trial, NOV-ERA, in the coming months.
SEC filing
Monte Rosa reports Phase 1 data for MRT-8102 in cardiovascular risk study
The company said its NEK7 degrader lowered multiple inflammatory markers tied to atherosclerosis and plans three Phase 2 trials starting as early as late 2026.
SEC filing
Sources
SEC EDGAR
8-K, 10-K, 10-Q, S-1, 424B, Form D, 13D/G, DEF 14A. Every watched filer, within minutes of filing.
FDA
Drugs@FDA approvals and labels, enforcement and recalls, drug shortages, FDA press releases, and what's new for drugs and biologics.
ClinicalTrials.gov
New and updated studies by sponsor and condition, with every change versioned.
Every stored document keeps its source URL and every story cites its sources. Stories are original summaries written from the record, checked against it, and corrected in the open when they are wrong.
Coverage
Which companies and drugs
Every biopharma company listed on Nasdaq or the NYSE, private biotechs that have filed a Form D with the SEC, and the large non-U.S. pharma companies that sponsor trials and hold FDA approvals. Every drug with an active FDA application and every investigational product in trials those companies lead, under its brand, generic, and code names. Watch lists can hold any company or drug.
How often
SEC EDGAR is polled every ten minutes during U.S. market hours and hourly otherwise. FDA press releases and the What's New feeds every thirty minutes. Drugs@FDA actions, recalls, shortages, and ClinicalTrials.gov updates daily, since those sources publish in daily batches.
How far back
The record starts June 27, 2026, ninety days before launch, and grows from there. Ninety days covers a full quarterly cycle (earnings 8-Ks, a 10-Q, proxy season) so a company page has context, while the feed stays what it is: what happened recently, not an archive. Anything older is one click away in the linked source, which is the archive of record.
Not covered yet
Company press releases and investor-relations pages, so news a company announces without filing an 8-K or updating a registry. The EMA and other non-U.S. regulators. Medical conferences and abstracts. Journal publications. Patents and patent litigation. If you rely on any of these, keep your current source for it; we will say here when that changes.
Never included
No trade press, news sites, analyst notes, or wire copy. If a claim is not in a public document, it is not in a readthrough story.
Pricing
$29 / seat / month
or $300 a year, 14% less
- Watch lists for the companies, drugs, and targets you follow
- Original summaries, each linked to its FDA, SEC, or ClinicalTrials.gov source
- Daily email digest at the hour you choose
- Private RSS feeds and Slack or Teams posts
- Search across every filing, approval, and trial in the corpus
No card until you decide. Cancel any time.
Enterprise
Everyone at your company signs in with their work email, no seats to count. Shared watch lists with their own feeds and digests, a workspace admin, invoicing, and single sign-on on the roadmap.
Or write to hello@readthrough.news.
Questions
What is readthrough?
A biotech intelligence feed built only from primary sources. It reads FDA, SEC, and ClinicalTrials.gov records as they update, writes an original summary of each development, and links every claim to the document it came from. You watch companies and drugs and get the stories that matter by web, email digest, RSS, Slack, or Teams.
Where does the information come from?
SEC EDGAR filings (8-K, 10-K, 10-Q, S-1, 424B, Form D, 13D/G, DEF 14A), FDA sources (Drugs@FDA approvals, enforcement and recalls, drug shortages, FDA press releases, and the What's New feeds for drugs and biologics), and ClinicalTrials.gov. No news sites, trade press, or wire copy.
What does readthrough not cover?
Today: company press releases and IR pages (unless the news is also in an SEC filing, an FDA record, or a trial registry), the EMA and other non-U.S. regulators, conference abstracts, journal publications, and patents. The coverage section above lists what is monitored and how often.
How are stories written and checked?
An AI language model writes each story from the source documents with a citation on every factual sentence, and a second automated pass checks each claim against those documents. A sentence the check cannot confirm is removed and the story says so; a story that cannot be supported as written is published as a short notice linking to the record instead. Stories publish without a person reviewing them first, and corrections are shown on the story when a published one is wrong.
How current is the feed?
New filings are stored within minutes of appearing on EDGAR, and stories usually publish within the hour. FDA and ClinicalTrials.gov sources are read on their own publication schedules, from every thirty minutes to daily.
How far back does the data go?
To June 27, 2026, ninety days before launch, and forward from there. The feed is about what is happening now; older history is available in the linked source documents.
Which drugs does it know about?
Every drug with an active FDA application (NDA or BLA), with its brand names, generic name, and first approval date from Drugs@FDA, plus every investigational product in trials led by a covered company, under the sponsor codes and nonproprietary names the registry uses. A drug's page shows who develops it, its aliases, and every story that names it.
Is readthrough investment advice?
No. Stories are summaries of public records. They contain no ratings, price targets, or recommendations, and nothing on the site is a suggestion to buy or sell any security.
How much does it cost?
$29 per seat per month, or $300 per seat per year. Every plan starts with a 14-day free trial with all features and no card required. Companies that want everyone on their email domain to sign in without seat counting can request enterprise access at app.readthrough.bio/enterprise.
Can I get stories into Slack or Teams?
Yes. Workspace admins add a Slack incoming webhook or a Teams Workflows webhook under Settings, per watch list or for the whole workspace, and new stories post as they publish. Private RSS feeds and a daily email digest are also included.
Is there an API?
Yes. A read API returns stories with their citations, company and drug profiles, search, and your watch lists as JSON, with per-workspace keys created in Settings. An MCP server gives AI assistants the same access with the same key. The reference is in the app once you sign in.